147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial

BACKGROUND: Fosmanogepix (FMGX) is a first-in-class antifungal agent, with a unique MOA targeting the fungal enzyme Gwt1, that has broad-spectrum activity against both yeasts, molds, and dimorphic fungi, including fungi resistant to other antifungal agents. FMGX has a favorable safety profile, reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappas, Peter, Kullberg, Bart Jan, Vazquez, Jose A, Oren, Ilana, Rahav, Galia, Aoun, Mickaël, Bulpa, Pierre, Ben-Ami, Ronen, Ferrer, Ricard, McCarty, Todd P, Thompson III, George R, Barbat, Sara, Wedel, Pamela, Oborska, Iwonka, Schlamm, Haran T, Hodges, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777973/
http://dx.doi.org/10.1093/ofid/ofaa439.457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777973/
http://dx.doi.org/10.1093/ofid/ofaa439.457

Ejemplares similares